Oncology Clinical Trials in Stony Brook, NY
As of July 2026, 51 paid clinical trials are recruiting for Oncology in Stony Brook, New York. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
51 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Project: Every Child for Younger Patients With Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Raman Spectroscopy and Skin Cancer
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Definitive Radiation Therapy for Inoperable Breast Cancer
About research studies in Stony Brook
Stony Brook has approximately 172 recruiting research studies across a wide range of therapeutic areas. New York is home to leading academic medical centers such as Memorial Sloan Kettering, Weill Cornell Medicine, Mount Sinai, NYU Langone, and Columbia University Irving Medical Center. These institutions anchor a research ecosystem that covers oncology, cardiology, neurology, and rare disease.
Top Research Study Locations in Stony Brook
Researchers run research studies in Stony Brook, NY at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Stony Brook University Medical Center | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, Acute Myeloid Leukemia Post Cytotoxic Therapy | 64 |
| Stony Brook University Hospital | Intracerebral Hemorrhage, Aneurysm, Intracranial, Anxiety | 32 |
| Stony Brook University | Opioid Use Disorder, Aneurysm, Brain, Atrial Fibrillation | 13 |
| Stony Brook Medicine | Focal Epilepsy, Hypertension, Abdominal Aortic Aneurysm | 12 |
| Stony Brook University Cancer Center | Breast Cancer, Breast Adenocarcinoma, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma) | 6 |
| Stony Brook Cancer Center | Acute Myeloid Leukemia, AML, AML With Mutated NPM1 | 4 |
| Nkarta Investigational Site | Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Lupus Nephritis | 2 |
| Stony Brook Children's Hospital | Congenital CMV Infection, Failed or Difficult Intubation, Sequela, Intubation Complication | 2 |
| Stony Brook University: Dept of Psychiatry | Major Depressive Disorder (MDD) | 2 |
| Anthos Investigative | Atrial Fibrillation (AF) | 1 |
| Ascentage Investigative | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Ph+ ALL | 1 |
| Elyse S. Rafal, MD PC - Rafal Center for Dermatology & Cosmetic Surgery | Plaque Psoriasis | 1 |
| GSK Investigational Site | Multiple Myeloma, Newly Diagnosed Multiple Myeloma | 1 |
| Investigative | Hidradenitis Suppurativa (HS) | 1 |
| Local Institution - 0111 | Lupus Erythematosus, Systemic, Lupus Nephritis | 1 |
| Local Institution - 0221 | Relapsed or Refractory Multiple Myeloma (RRMM) | 1 |
| Renaissance School of Medicine Stony Brook University | Cesarean Delivery, General Anesthesia | 1 |
| SUNY Stony Brook | Hepatitis C | 1 |
| Site 5040, SUNY Stony Brook NICHD CRS | Pregnancy | 1 |
| Stony Brook | Vein Disease, Vein Occlusion, Vein Thrombosis | 1 |
| Stony Brook Advanced Specialty Care | Interstitial Lung Disease, Progressive Pulmonary Fibrosis | 1 |
| Stony Brook Breast Center | Breast Cancer, HER2-positive Breast Cancer, Locally Advanced Breast Cancer | 1 |
| Stony Brook Cancer Center | Non-Small Cell Lung Cancer | 1 |
| Stony Brook Heart Institute | Tricuspid Regurgitation, Tricuspid Regurgitation Functional | 1 |
| Stony Brook Hospital | Basal Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma | 1 |
Active & Upcoming Studies in Stony Brook (2026)
Recruiting trials in Stony Brook grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (88 active studies)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · National Cancer Institute (NCI)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer · Phase 3 · National Cancer Institute (NCI)
Cardiovascular (14 active studies)
- Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258) · Phase 3 · Reprieve Cardiovascular, Inc
- The VENTOR Clinical Study · CoLabs Medical
Neurology & pain (10 active studies)
- The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms · phenox Inc.
- MMA Embolization for Refractory Chronic Migraine · Cerenovus, Part of DePuy Synthes Products, Inc.
Mental health & behavior (2 active studies)
Vaccines (1 active study)
HIV / STI (1 active study)
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV · Phase 1, Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
Pediatric (1 active study)
- Monetary Incentive Delay Task for Probing Reward-related Neural Processes · Stony Brook University
Common conditions studied in Stony Brook
- Acute Myeloid Leukemia (10 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Breast Cancer (8 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Acute Myeloid Leukemia Post Cytotoxic Therapy (3 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Heart Failure (3 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Intracerebral Hemorrhage (3 active studies). Recruiting Intracerebral Hemorrhage studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Stony Brook
- National Cancer Institute (NCI)
- Stony Brook University
- Children's Oncology Group
- AstraZeneca
- NRG Oncology
Local regulations and guidelines
Clinical trials in New York are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials conducted in New York must also comply with the NY SHIELD Act's data-protection requirements and additional oversight from the New York State Department of Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Stony Brook. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Stony Brook
Hipa.ai aggregates every recruiting study in Stony Brook from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Stony Brook?
There are approximately 172 recruiting clinical trials in Stony Brook, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Stony Brook pay participants?
Most recruiting trials in Stony Brook compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Stony Brook?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Stony Brook?
The most common conditions under active study in Stony Brook include Acute Myeloid Leukemia (10), Breast Cancer (8), Anatomic Stage II Breast Cancer AJCC v8 (4), Acute Myeloid Leukemia Post Cytotoxic Therapy (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Stony Brook?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Stony Brook on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Stony Brook?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Stony Brook?
Recruiting research sites in Stony Brook include Stony Brook University Medical Center, Stony Brook University Hospital, Stony Brook University, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Stony Brook right now?
The largest active categories in Stony Brook are Cancer & tumors (88), Cardiovascular (14), Neurology & pain (10). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.